Hansa Medical announces prospectus

Important information
The information in this press release is not directed at persons located in
Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea,
Singapore, South Africa, Switzerland, the United States or any other country
where the offer or sale of subscription rights, interim shares or new shares is
not permitted. The information may not be published or distributed, directly or
indirectly, in or into, any of the aforementioned countries or any other country
where such action is wholly or partially subject to legal restrictions or where
such action would require additional prospectuses, other offer documentation,
registrations or other actions in addition to what follows from Swedish law. Nor
may the information be forwarded, reproduced or disclosed in such a manner that
contravenes such restrictions or gives cause to such requirements. Failure to
comply with these instructions may result in a violation of the United States
Securities Act of 1933, as amended (“Securities Act”) or laws applicable in
other jurisdictions.

The information in this press release does not contain or constitute an
invitation or an offer to acquire, sell, subscribe for or otherwise trade in
shares, subscription rights or other securities in Hansa Medical AB. No
subscription rights, interim shares or new shares will be registered under the
Securities Act or in accordance with any other rules or regulations in any other
country than Sweden and may not be transferred or offered for sale in the United
States or any country where such transfer or offer may be prohibited, or to
persons resident in any such country or on account of such persons, other than
pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act or similar legislation in
another country, respectively.

The Board of Hansa Medical AB (publ) has prepared a prospectus due to the
listing. The prospectus has today, October 27, 2015, been approved by and
registered with the Swedish Financial Supervisory Authority (Sw.
Finansinspektionen) in accordance with the Financial Instruments Trading Act
(Sw. lagen (1991:980) om handel med finansiella instrument).

The prospectus is available on Hansa Medical’s website (www.hansamedical.com)
and will be available on the Swedish Financial Supervisory Authority’s website
(www.fi.se/Register/Prospektregistret).

The prospectus contains revised financial statements of historical financial
information regarding the financial years of 2012, 2013 and 2014, which have
been audited by the company’s auditor.

The first day of trading is planned to fall on November 2, 2015.

The information in this press release was released for public disclosure on
October 27, 2015 at 08.00 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70-390 85 30
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory
enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical
development, with potential use in transplantation and rare autoimmune diseases.
Other projects include HBP (a market introduced diagnostic marker for severe
sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical
development). The company is based in Lund, Sweden. Hansa Medical's share
(HMED) is listed on First North Premier in Stockholm with Remium Nordic AB as
Certified Adviser.